bronchial asthma in acute exacerbation
... Salmeterol: maximal bronchodilation about 1 hr after administration Formoterol: onset of action within 5–10 min. for individuals who require frequent SABA use during the day to prevent exercise-induced bronchospasm an “add-on” agent in patients who are suboptimally controlled on ICS therapy ...
... Salmeterol: maximal bronchodilation about 1 hr after administration Formoterol: onset of action within 5–10 min. for individuals who require frequent SABA use during the day to prevent exercise-induced bronchospasm an “add-on” agent in patients who are suboptimally controlled on ICS therapy ...
Tegretol PI
... not develop SJS/TEN and patients negative for HLA-B*1502 of any ethnicity can still develop SJS/TEN. Similarly many patients positive for HLA-A*3101 and treated with Tegretol will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A*3101 of any ethnicity can still ...
... not develop SJS/TEN and patients negative for HLA-B*1502 of any ethnicity can still develop SJS/TEN. Similarly many patients positive for HLA-A*3101 and treated with Tegretol will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A*3101 of any ethnicity can still ...
The New England Journal Of Medicine
... are rare occurrences, and the system is suspended in “code” situations when medications are needed instantly. Early data from the hospital pharmacy suggest that the system is already making a difference in patient safety. Bar coding has reduced drug errors by more than 50 percent, preventing approxi ...
... are rare occurrences, and the system is suspended in “code” situations when medications are needed instantly. Early data from the hospital pharmacy suggest that the system is already making a difference in patient safety. Bar coding has reduced drug errors by more than 50 percent, preventing approxi ...
Acetylcysteine for Acetaminophen Overdose
... loading dose, then 70 mg/kg every 4 hours for 17 doses starting 4 hours after the loading dose. Oral NAC is irritating to the gastrointestinal track and should be diluted to a final concentration of no more than 5% to reduce the risk for vomiting. The oral form of NAC has an unpleasant odor and tast ...
... loading dose, then 70 mg/kg every 4 hours for 17 doses starting 4 hours after the loading dose. Oral NAC is irritating to the gastrointestinal track and should be diluted to a final concentration of no more than 5% to reduce the risk for vomiting. The oral form of NAC has an unpleasant odor and tast ...
Bronchial Asthma Pathophysiology and management
... Stepping down treatment when asthma is controlled When controlled on medium‐ to high‐dose inhaled glucocorticosteroids: 50% dose reduction at 3 month intervals (Evidence B) When controlled on low‐dose inhaled glucocorticosteroids: switch to once‐daily dosing (Evidence A) ...
... Stepping down treatment when asthma is controlled When controlled on medium‐ to high‐dose inhaled glucocorticosteroids: 50% dose reduction at 3 month intervals (Evidence B) When controlled on low‐dose inhaled glucocorticosteroids: switch to once‐daily dosing (Evidence A) ...
1 “Challenging Cases in the Diagnosis and - Power
... 251 patients at-risk for invasive aspergillosis and being evaluated for unexplained nodular lesions or consolidation on lung imaging, the BAL galactomannan optical density of greater than or equal to 0.8 yielded a sensitivity of 86% and a specificity of 91% for diagnosing either proven or probable i ...
... 251 patients at-risk for invasive aspergillosis and being evaluated for unexplained nodular lesions or consolidation on lung imaging, the BAL galactomannan optical density of greater than or equal to 0.8 yielded a sensitivity of 86% and a specificity of 91% for diagnosing either proven or probable i ...
Overview of the therapy of heart failure due to systolic dysfunction
... hypertension imposes an increased hemodynamic load on the failing ventricle in patients with established HF due to any etiology. The goals of therapy are to control blood pressure and to reduce left ventricular afterload, thereby improving cardiac function and decreasing the progression of pathologi ...
... hypertension imposes an increased hemodynamic load on the failing ventricle in patients with established HF due to any etiology. The goals of therapy are to control blood pressure and to reduce left ventricular afterload, thereby improving cardiac function and decreasing the progression of pathologi ...
ASTHMA MANAGEMENT: 5–11 YEARS OF AGE
... • Caution: Increasing use of SABA or use >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment ...
... • Caution: Increasing use of SABA or use >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment ...
Somatostatin, octreotide and gabexate mesilate in the therapy of
... – Randomized trials: high dose bolus and continuous-infusion PPI have shown ↓rebleeding, ↓need for surgery compared with H2 blocker or placebo – Meta-analyses: high dose PPI after successful endoscopic therapy ↓rebleeding – RUGBE: PPI ↓rebleeding, mortality in high-risk patient, trend toward ↓reblee ...
... – Randomized trials: high dose bolus and continuous-infusion PPI have shown ↓rebleeding, ↓need for surgery compared with H2 blocker or placebo – Meta-analyses: high dose PPI after successful endoscopic therapy ↓rebleeding – RUGBE: PPI ↓rebleeding, mortality in high-risk patient, trend toward ↓reblee ...
Palliative Care for Patients With Head and Neck Cancer
... has no risk factors for oral cancer, specifically no tobacco use or significant alcohol intake. In 1997, he developed a tongue lesion that demonstrated dysplasia. It was treated with topical steroids, and then both laser and surgical excision. The lesion recurred in 1999 and a biopsy revealed superf ...
... has no risk factors for oral cancer, specifically no tobacco use or significant alcohol intake. In 1997, he developed a tongue lesion that demonstrated dysplasia. It was treated with topical steroids, and then both laser and surgical excision. The lesion recurred in 1999 and a biopsy revealed superf ...
Guidelines for the management of inflammatory bowel disease in
... treatment in the first 10 years of disease and approximately 70–80% will require surgery within their lifetime. The overall mortality of CD is slightly higher than the normal population and is greatest in the 2 years after diagnosis or in those with upper gastrointestinal disease. The clinical cours ...
... treatment in the first 10 years of disease and approximately 70–80% will require surgery within their lifetime. The overall mortality of CD is slightly higher than the normal population and is greatest in the 2 years after diagnosis or in those with upper gastrointestinal disease. The clinical cours ...
pneumonia
... acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community. Hospital-acquired (or nosocomial) pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission . Ventilator-associated p ...
... acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community. Hospital-acquired (or nosocomial) pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission . Ventilator-associated p ...
0018
... insulin syringe. A sample of 0.25 – 0.5 mL of buffy-coat suspension containing 200,000 to 400,000 cells was injected intralesionally by the dermatologist using multiple injection sites. This therapy was repeated at one-week interval injections for three times. At the beginning of the fourth week, th ...
... insulin syringe. A sample of 0.25 – 0.5 mL of buffy-coat suspension containing 200,000 to 400,000 cells was injected intralesionally by the dermatologist using multiple injection sites. This therapy was repeated at one-week interval injections for three times. At the beginning of the fourth week, th ...
Ethical Considerations in Access to Experimental Drugs
... ethical debates about the extent to which patients should dictate their own course of treatment, questions that take on additional gravity when they concern decisions made at the end of life. One such question is whether dying patients who have exhausted standard therapy should be permitted to attem ...
... ethical debates about the extent to which patients should dictate their own course of treatment, questions that take on additional gravity when they concern decisions made at the end of life. One such question is whether dying patients who have exhausted standard therapy should be permitted to attem ...
CHAPTER 7 Managing Side Effects of Multikinase Inhibitors
... Hypertension is a commonly reported side effect of therapy in patients taking either of the multikinase inhibitors. In the HCC population, hypertension was reported in 9.4% of patients treated with sorafenib compared with 4.3% of patients treated with placebo.1 Treatment-emergent hypertension was re ...
... Hypertension is a commonly reported side effect of therapy in patients taking either of the multikinase inhibitors. In the HCC population, hypertension was reported in 9.4% of patients treated with sorafenib compared with 4.3% of patients treated with placebo.1 Treatment-emergent hypertension was re ...
Asthma report- edited - MEDICINE DEPARTMENT of MMC
... Inadequate response to therapy within 1-2 hours Persistent PEF <50% after 1 hour of treatment Presence of risk factors Prolong symptoms prior to ER consult Inadequate access to medical care and medications • Difficult home condition • Difficulty in obtaining transport to hospital in event of further ...
... Inadequate response to therapy within 1-2 hours Persistent PEF <50% after 1 hour of treatment Presence of risk factors Prolong symptoms prior to ER consult Inadequate access to medical care and medications • Difficult home condition • Difficulty in obtaining transport to hospital in event of further ...
Ceftobiprole: A New Option for Treatment of Skin and Soft
... 656 • CID 2008:46 (1 March) • EDITORIAL COMMENTARY ...
... 656 • CID 2008:46 (1 March) • EDITORIAL COMMENTARY ...
Nonmedication, Alternative, and Complementary
... Recent Findings: In addition to the established nonpharmacologic therapies, such as biofeedback, relaxation training, butterbur, riboflavin, magnesium, and coenzyme Q10 (CoQ10) supplementation, recent data provide support for the use of aerobic exercise and acupuncture. Discovery of the high inciden ...
... Recent Findings: In addition to the established nonpharmacologic therapies, such as biofeedback, relaxation training, butterbur, riboflavin, magnesium, and coenzyme Q10 (CoQ10) supplementation, recent data provide support for the use of aerobic exercise and acupuncture. Discovery of the high inciden ...
introduction
... There are currently 10,65,000 people on Hemodialysis worldwide (European dialysis and transplant nurses association \European Renal Care Association Journal,2005).CKD will kill 36 million people by the year 2015. In India 10 lakh people suffer from kidney failure and more than 4 crores are at risk ...
... There are currently 10,65,000 people on Hemodialysis worldwide (European dialysis and transplant nurses association \European Renal Care Association Journal,2005).CKD will kill 36 million people by the year 2015. In India 10 lakh people suffer from kidney failure and more than 4 crores are at risk ...
Expanding Allergy Treatment in Primary Care
... Dosing of sublingual therapy likely requires several times the concentrations used for subcutaneous immunotherapy Data from European studies suggest efficacy with a favorable safety profile Most studies of SLIT have been with single allergens and translation of these studies to treatment with multip ...
... Dosing of sublingual therapy likely requires several times the concentrations used for subcutaneous immunotherapy Data from European studies suggest efficacy with a favorable safety profile Most studies of SLIT have been with single allergens and translation of these studies to treatment with multip ...
Statins and Myalgia: A case Report of Pharmacovigilance
... combinations of elevated serum total cholesterol (hypercholesterolemia), elevated lowdensity lipoproteins, elevated triglycerides (hypertriglyceridemia) and decreased highdensity lipoproteins. These abnormalities are the primary risk factors for artherosclerosis and coronary artery disease.4-8 Data ...
... combinations of elevated serum total cholesterol (hypercholesterolemia), elevated lowdensity lipoproteins, elevated triglycerides (hypertriglyceridemia) and decreased highdensity lipoproteins. These abnormalities are the primary risk factors for artherosclerosis and coronary artery disease.4-8 Data ...
HIGHLIGHTS OF PRESCRIBING INFORMATION __________________ CONTRAINDICATIONS ____________________
... adequate and well-controlled studies of the combined or sequential use of FEIBA and recombinant factor VIIa or antifibrinolytics have been conducted. Use of antifibrinolytics within approximately 6 to 12 hours after the administration of FEIBA is not recommended. 8. USE IN SPECIFIC POPULATIONS 8.1 P ...
... adequate and well-controlled studies of the combined or sequential use of FEIBA and recombinant factor VIIa or antifibrinolytics have been conducted. Use of antifibrinolytics within approximately 6 to 12 hours after the administration of FEIBA is not recommended. 8. USE IN SPECIFIC POPULATIONS 8.1 P ...
High-dose beclomethasone: oral steroid-sparing effect J. Lacronique*
... baled salbutamol. They had chronic asthma since the disease had been diagnosed more than 10 yrs earlier for most of them. Severity was assessed from the require· ment for daily maintenance treatment with corticosteroids. For inclusion, patients had to be treated with 5 mg or more per day of oral pre ...
... baled salbutamol. They had chronic asthma since the disease had been diagnosed more than 10 yrs earlier for most of them. Severity was assessed from the require· ment for daily maintenance treatment with corticosteroids. For inclusion, patients had to be treated with 5 mg or more per day of oral pre ...
Antiparasitic Therapy in Children
... is the recommended first-line treatment regimen for pregnant women with chloroquine-resistant malaria. Quinine sulfate is a relatively safe drug, although it may produce a syndrome known as cinchonism (name derived from the cinchona tree, from which quinine is extracted). Cinchonism is a symptom com ...
... is the recommended first-line treatment regimen for pregnant women with chloroquine-resistant malaria. Quinine sulfate is a relatively safe drug, although it may produce a syndrome known as cinchonism (name derived from the cinchona tree, from which quinine is extracted). Cinchonism is a symptom com ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.